Answers are grounded in this paper and cite their sources.
In the absence of approved pharmacotherapy for sarcopenia, selected traditional Chinese medicine (TCM) preparations—including multi-herb formulae, botanical extracts, and isolated bioactive metabolites—have attracted experimental interest, but the reliability and clinical relevance of the evidence remain uncertain. This critical narrative review synthesizes English- and Chinese-language preclinical literature identified through PubMed, Web of Science, CNKI, and Wanfang Data from 1 January 2010 to 30 June 2026. The evidence base comprises 89 intervention entries from 88 reports and 129 distinct study–model combinations, classified as primary-ageing, secondary-context, or acute-atrophy/ in-vitro evidence. Across the specific preparations studied, reported findings mainly concerned protein turnover, inflammatory and fibrotic signaling, mitochondrial quality control, oxidative stress, and satellite-cell regulation. Most findings were treatment–marker associations: only 48/89 entries (53.9%) reported a functional endpoint, while chemical characterization, dose justification, multidose evaluation, causal validation, and safety reporting were limited. Clinical studies remain small and heterogeneous. Overall, the literature supports product-specific biological hypotheses, but clinical efficacy remains unestablished. Priorities for further validation and clinical evaluation are briefly outlined.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: